Characterization of intermediate steps in amyloid beta (Aβ) production under near-native conditions

Fredrik Olsson1, Staffan Schmidt, Veit Althoff

  • 1From the AstraZeneca iMED CNS/Pain, 15185 Södertälje, Sweden.

Insights

This study reveals intermediate steps in amyloid precursor protein (APP) processing by γ-secretase, clarifying Alzheimer's disease (AD) mechanisms. Familial AD mutations and γ-secretase modulators (GSMs) alter amyloid-beta (Aβ) peptide production pathways.

Area of Science:

  • Neuroscience
  • Biochemistry
  • Molecular Biology

Background:

  • Amyloid precursor protein (APP) processing by γ-secretase generates amyloid-beta (Aβ) peptides.
  • Accumulation of Aβ, particularly Aβ42, is linked to familial Alzheimer's disease (FAD).
  • The precise mechanisms of normal Aβ production, FAD mutation impact, and γ-secretase modulator (GSM) effects remain unclear.

Purpose of the Study:

  • To elucidate the molecular mechanisms of Aβ production.
  • To investigate the impact of FAD mutations on Aβ generation.
  • To understand how GSMs selectively reduce Aβ40 and Aβ42 levels.

Main Methods:

  • Utilized a combined immuno- and liquid chromatography-mass spectrometry (LC-MS) assay.
  • Identified major intermediate peptides (3- and 4-residue fragments) across the APP transmembrane sequence.
  • Analyzed Aβ production in the context of FAD mutations and GSM treatment.

Main Results:

  • Identified key intermediate peptides (e.g., Aβ51-30, Aβ49-30) in APP processing.
  • FAD mutations increased specific intermediate peptides (Aβ48-38), correlating with higher Aβ42/40 ratios.
  • GSMs decreased Aβ40/42 and increased shorter peptides (Aβ37/38) and specific intermediates (Aβ40-38, Aβ42-39).

Conclusions:

  • Provided a comprehensive characterization of Aβ production intermediates in native cell membranes.
  • Offered mechanistic insights into genetic and pharmacological modulation of Aβ generation.
  • Established a foundation for understanding and targeting Alzheimer's disease pathogenesis.